Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

Despite declines in heart failure morbidity and mortality with current therapies,
rehospitalization rates remain distressingly high, substantially affecting individuals, society …

Our understanding of the functions of cardiac fibroblasts has moved beyond their roles in
heart structure and extracellular matrix generation and now includes their contributions to …

▪ Abstract Statins are potent inhibitors of cholesterol biosynthesis. In clinical trials, statins are
beneficial in the primary and secondary prevention of coronary heart disease. However, the …

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …

▪ Abstract Cardiac fibroblasts play a central role in the maintenance of extracellular matrix in
the normal heart and as mediators of inflammatory and fibrotic myocardial remodeling in the …

Currently, five different statins (simvastatin, pravastatin, lovastatin, fluvastatin, and
atorvastatin) are approved for treatment of hypercholesterolemia in humans and two new …

The increase in heart failure (HF) rates throughout the developed and developing regions of
the world poses enormous challenges for caregivers, researchers, and policymakers …

Adverse cardiac remodeling leads to impaired ventricular function and heart failure,
remaining a major cause of mortality and morbidity in patients with acute myocardial …

Statins are 3-hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which
are prescribed extensively for cholesterol lowering in the primary and secondary prevention …